Alimentary Pharmacology & Therapeutics

Review article: nucleoside analogues for the treatment of chronic hepatitis B
pp. 1211-1230(20)
Authors: Younger, H. M.; Bathgate, A. J.; Hayes, P. C.

Review article: the eosinophil as a therapeutic target in gastrointestinal disease
pp. 1231-1240(10)
Authors: Hogan, S. P.; Rothenberg, M. E.

Systematic review: is there excessive use of proton pump inhibitors in gastro-oesophageal reflux disease?
pp. 1241-1251(11)
Authors: Lee, T. J.; Fennerty, M. B.; Howden, C. W.

Meta-analysis: the treatment of irritable bowel syndrome
pp. 1253-1269(17)
Authors: Lesbros-Pantoflickova, D.; Michetti, P.; Fried, M.; Beglinger, C.; Blum, A. L.

Meta-analysis: effect of hepatitis C virus infection on mortality in dialysis
pp. 1271-1277(7)
Authors: Fabrizi, F.; Martin, P.; Dixit, V.; Bunnapradist, S.; Dulai, G.

Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast)
pp. 1279-1287(9)
Authors: Melzer, J.; Rösch, W.; Reichling, J.; Brignoli, R.; Saller, R.

Endoscopic ablation of Barrett's oesophagus: a randomized-controlled trial of photodynamic therapy vs. argon plasma coagulation
pp. 1289-1296(8)
Authors: Kelty, C. J.; Ackroyd, R.; Brown, N. J.; Stephenson, T. J.; Stoddard, C. J.; Reed, M. W. R.

Irritable bowel, smoking and oesophageal acid exposure: an insight into the nature of symptoms of gastro-oesophageal reflux
pp. 1297-1303(7)
Author: Zimmerman, J.

The usual medical care for irritable bowel syndrome
pp. 1305-1315(11)
Authors: Whitehead, W. E.; Levy, R. L.; Von Korff, M.; Feld, A. D.; Palsson, O. S.; Turner, M.; Drossman, D. A.

Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario
pp. 1317-1322(6)
Authors: Marshall, J. K.; Thabane, M.; Garg, A. X.; Clark, W.; Meddings, J.; Collins, S. M.

A prospective assessment of cytomegalovirus infection in active inflammatory bowel disease
pp. 1323-1327(5)
Authors: Saussure, P.; Lavergne-Slove, A.; Mazeron, M.-C.; Alain, S.; Matuchansky, C.; Bouhnik, Y.

Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double-blind placebo-controlled study
pp. 1329-1336(8)
Authors: West, R. L.; Woude, C. J.; Hansen, B. E.; Felt-Bersma, R. J. F.; Tilburg, A. J. P.; Drapers, J. A. G.; Kuipers, E. J.

Intravenous CDP870, a PEGylated Fab′ fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study
pp. 1337-1346(10)
Authors: Winter, T. A.; Wright, J.; Ghosh, S.; Jahnsen, J.; Innes, A.; Round, P.

Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study
pp. 1347-1352(6)
Authors: Domènech, E.; Hinojosa, J.; Esteve-Comas, M.; Gomollón, F.; Herrera, J. M.; Bastida, G.; Obrador, A.; Ruiz, R.; Saro, C.; Gassull, M. A.

Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis - results from a randomized-controlled trial
pp. 1353-1363(11)
Authors: Raedler, A.; Behrens, C.; Bias, P.

Ultrase MT12 and Ultrase MT20 in the treatment of exocrine pancreatic insufficiency in cystic fibrosis: safety and efficacy
pp. 1365-1371(7)
Authors: Konstan, M. W.; Stern, R. C.; Trout, J. R.; Sherman, J. M.; Eigen, H.; Wagener, J. S.; Duggan, C.; Wohl, M. E. B.; Colin, P.

Oesophageal pH has a power-law distribution in control and gastro-oesophageal reflux disease subjects
pp. 1373-1379(7)
Authors: Gardner, J. D.; Sloan, S.; Robinson, M.; Miner, P. B.

Frequency analyses of gastric pH in control and gastro-oesophageal reflux disease subjects treated with a proton-pump inhibitor
pp. 1381-1386(6)
Authors: Gardner, J. D.; Sloan, S.; Robinson, M.; Miner Jr, P. B.

Corrigenda
pp. 1387-1388(2)

Erratum
pp. 1389-1389(1)

Index
pp. 1391-1406(16)